Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)

Despite high response rates after initial chemotherapy in patients with acute myeloid leukemia (AML), relapses occur frequently, resulting in a five-year-survival by <30% of the patients. Hitherto, allogeneic hemotopoietic stem cell transplantation (allo-HSCT) is the best curative treatment optio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hofmann, Susanne, Schubert, Maria-Luisa, Wang, Lei, He, Bailin, Neuber, Brigitte, Dreger, Peter, Müller-Tidow, Carsten, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/
https://www.ncbi.nlm.nih.gov/pubmed/30736352
http://dx.doi.org/10.3390/jcm8020200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406805/
https://www.ncbi.nlm.nih.gov/pubmed/30736352
http://dx.doi.org/10.3390/jcm8020200

Ejemplares similares